Shannon Morris Biography and Net Worth

Chief Medical Officer of Erasca

Shannon brings over 20 years of experience in the life sciences with a focus in oncology. She joined Erasca from Istari Oncology, where she was Vice President, Head of Clinical Development, and a member of the executive committee. Prior to joining Istari, she was Vice President of Clinical Development at G1 Therapeutics where she led the development of Cosela^™, achieving breakthrough therapy designation as well as a successful NDA. As a senior director at MedImmune, the global biologics research and development arm of AstraZeneca, she supported the successful biologics license application (BLA) for Imfinzi^® and led the development of multiple early phase immuno-oncology assets. At GlaxoSmithKline, she held roles of increasing responsibility where her efforts focused on the early phase development of small molecule inhibitors of AKT, PI3K, and MEK, including the approved MEK inhibitor Mekinist^®. During her time at GlaxoSmithKline and MedImmune, Shannon maintained an adjunct appointment at the University of North Carolina where her practice focused on the clinical care of patients with breast and gastrointestinal cancers.

Shannon completed her internal medicine residency and oncology fellowship at the University of North Carolina, earned an M.D. and Ph.D. in molecular virology from Case Western Reserve University, and holds a B.S. in biological sciences from Stanford University.

How old is Shannon Morris?: Dr. Morris is currently 54 years old. There are 7 older executives and no younger executives at Erasca. The oldest executive at Erasca is Dr. Michael D. Varney Ph.D., Chairman of Research & Development, Scientific Advisory Board Member and Director, who is 66 years old. Learn More on Shannon Morris' age.
How do I contact Shannon Morris?: The corporate mailing address for Dr. Morris and other Erasca executives is , , . Erasca can also be reached via phone at 858-465-6511 and via email at [email protected]. Learn More on Shannon Morris' contact information.
Has Shannon Morris been buying or selling shares of Erasca?: During the last quarter, Shannon Morris has sold $300,800.00 in Erasca stock. Most recently, Shannon Morris sold 20,000 shares of the business's stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $15.04, for a transaction totalling $300,800.00. Learn More on Shannon Morris' trading history.
Who are Erasca's active insiders?: Erasca's insider roster includes Alexander Casdin (Director), Ebun Garner (General Counsel), Valerie Harding (Director), Jonathan Lim (Chairman, CEO and Co-founder), and Shannon Morris (Chief Medical Officer). Learn More on Erasca's active insiders.
Are insiders buying or selling shares of Erasca?: During the last year, insiders at the sold shares 2 times. They sold a total of 140,000 shares worth more than $971,600.00. The most recent insider tranaction occured on March, 4th when insider Shannon Morris sold 20,000 shares worth more than $300,800.00. Insiders at Erasca own 14.4% of the company. Learn More about insider trades at Erasca.
Information on this page was last updated on 3/4/2026.

Shannon Morris Insider Trading History at Erasca

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/4/2026	Sell	20,000	$15.04	$300,800.00

Shannon Morris Buying and Selling Activity at Erasca

Erasca Company Overview

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Today's Range

Now: $15.47

$14.97

$15.97

50 Day Range

MA: $9.87

$3.46

$15.54

2 Week Range

Now: $15.47

$1.01

$16.00

Volume

5,050,629 shs

Average Volume

6,718,814 shs

Market Capitalization

$4.79 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.16